Meneses Jucille, Bhandari Vineet, Alves Joao G
Division of Neonatology, Instituto de Medicina Integral Professor Fernando Figueira, Ave Boa Viagem 2080, Apt 2801, Recife, PE, Brazil.
Arch Pediatr Adolesc Med. 2012 Apr;166(4):372-6. doi: 10.1001/archpediatrics.2011.1142.
To determine among preterm infants with respiratory distress syndrome whether the use of early nasal intermittent positive-pressure ventilation (NIPPV) vs nasal continuous positive airway pressure (NCPAP) decreases the need for invasive ventilation within the first 72 hours of life.
MEDLINE, EMBASE, CINAHL, Cochrane Central Register of Controlled Trials, and clinicaltrials.gov were searched, as well as abstracts from meetings of the Pediatric Academic Societies.
Randomized controlled trials involving infants with respiratory distress syndrome who received NIPPV vs NCPAP.
Data were extracted on the use of NIPPV vs NCPAP. Also extracted were data on the need for invasive ventilation within the first 72 hours of life and the incidences of bronchopulmonary dysplasia, pneumothorax, necrotizing enterocolitis, and intraventricular hemorrhage, as well as the time to full feeds and the duration of hospital stay.
Three trials were included (n = 360). A significant decrease in the need for invasive ventilation was found in the NIPPV group (risk ratio, 0.60; 95% CI, 0.43-0.83). No difference between groups was found in the incidence of bronchopulmonary dysplasia (risk ratio, 0.56; 95% CI, 0.09-3.49). No differences in the other outcomes were observed between the 2 groups.
Among preterm infants with respiratory distress syndrome, NIPPV decreases the need for invasive ventilation within the first 72 hours of life compared with NCPAP. Trials are needed to assess whether NIPPV minimizes the occurrence of bronchopulmonary dysplasia and other comorbidities.
确定在患有呼吸窘迫综合征的早产儿中,早期使用鼻间歇正压通气(NIPPV)与鼻持续气道正压通气(NCPAP)相比,是否能降低出生后72小时内有创通气的需求。
检索了MEDLINE、EMBASE、CINAHL、Cochrane对照试验中央注册库以及clinicaltrials.gov,还检索了儿科学术协会会议的摘要。
涉及接受NIPPV与NCPAP治疗的呼吸窘迫综合征婴儿的随机对照试验。
提取了关于NIPPV与NCPAP使用情况的数据。还提取了出生后72小时内有创通气需求、支气管肺发育不良、气胸、坏死性小肠结肠炎和脑室内出血的发生率,以及完全经口喂养时间和住院时间的数据。
纳入了三项试验(n = 360)。NIPPV组有创通气需求显著降低(风险比,0.60;95%可信区间,0.43 - 0.83)。两组间支气管肺发育不良的发生率无差异(风险比,0.56;95%可信区间,0.09 - 3.49)。两组在其他结局方面未观察到差异。
在患有呼吸窘迫综合征的早产儿中,与NCPAP相比,NIPPV可降低出生后72小时内有创通气的需求。需要进行试验来评估NIPPV是否能将支气管肺发育不良和其他合并症的发生降至最低。